智通财经APP获悉，截止2月23日收盘，东北电气(00042)、京城机电股份(00187)、弘业期货(03678)分列 AH溢价率前三位，溢价率分别为757.14%、280.60%、278.12%；宁德时代(03750)、药明康德(02359)、 招商银行(03968)分列AH溢价率末三位，溢价率分别为-18.31%、-7.13%、-5.36%。其中郑州银行 (06196)、龙蟠科技(02465)、剑桥科技(06166)的偏离值位居前三，分别为14.55%、11.57%、10.92%；另 外，东北电气(00042)、长飞光纤光缆(06869)、晨鸣纸业(01812)的偏离值位居后三，分别 为-51.17%、-48.00%、-45.02%。 | 南华期货股份 | | | | | | --- | --- | --- | --- | --- | | (02691) | | | | | | 弘业期货(03678) | 3.200 | 10.1 | 278.12% | 6.85% | | 中国中免(01880) | 91.850 | 97.1 | 26.63% | 6.70% | | 金隅集团(02009) | 0.8 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

这些超预期的表现，不仅反映了上市公司实际财务表现优于市场预期，还彰显出良好的经营状况和稳健 的增长态势，为投资者带来信心，成为观察经济复苏和行业发展趋势的重要窗口。 据证券时报·数据宝统计，截至2月13日（下同），已公布2025年度业绩预告、业绩快报或者年报的上市 公司中，券商研报明确给予"超预期"评价的公司有56家。这份"超预期"名单中，一个清晰的轮廓浮现出 来：龙头公司正成为业绩增长的"领跑者"。 业绩超预期不仅反映企业自身的经营实力，也是宏观经济环境、行业趋势和政策导向的风向标。 业绩超预期公司名单出炉 春节前后，A股市场进入2025年年报业绩预告、快报的披露高峰期，部分上市公司通过一系列改革措 施，经营效率大幅提升，同时受益于产品供需格局优化、行业景气度提升以及资产处置等影响，实现了 业绩的超预期增长。 数据显示，这些业绩超预期的公司中，超过八成的A股市值超过100亿元，其中更是不乏紫金矿业、兴 业银行、新易盛、中信证券、药明康德等14家千亿市值巨头。这些头部企业正以其迅猛的成长性，重新 锚定产业价值，并吸引资本向高质量发展主线加速汇聚。 以有色金属龙头紫金矿业为例，公司预计2025年净利润为510亿 ...

Group 1 - In 2025, China's foreign trade showed strong resilience, with total exports reaching a historical high, growing by 5.5% year-on-year, despite a complex external environment [1][57] - China's trade surplus exceeded $1 trillion for the first time, marking a significant increase of 19.8% year-on-year [1][57] - The net export of goods and services contributed 1.64 percentage points to GDP growth, the second-highest level since 2007, only behind 2021 [3] Group 2 - The diversification of external demand has strengthened, with emerging markets compensating for the decline in exports to the US, which fell by 19.79% year-on-year [6] - Exports to ASEAN, Africa, and the Middle East saw significant growth rates of 25.9%, 13.64%, and 9.7% respectively, contributing positively to the overall export scale [6] - The share of US exports in China's total exports decreased by 3.53 percentage points to 11.15% [6] Group 3 - The product structure of China's foreign trade is shifting towards higher value chains, with high-end products like electrical machinery, machinery, automobiles, and ships being the main export drivers [8] - Traditional light industrial products such as furniture and toys have seen a decline in export scale due to tariff friction and industrial chain relocation [8] Group 4 - The restructuring of global supply chains is creating significant opportunities for Chinese companies, with a notable increase in the number of Chinese enterprises establishing production capacities abroad, reaching 229 in 2025, nearly doubling from 2024 [18] - ASEAN, Mexico, and India are the primary destinations for Chinese production capacity outflows, with ASEAN covering a wide range of industries [18] Group 5 - The AI expansion cycle is a core focus in the Chinese capital market, with significant growth expected in AI computing hardware, supported by macro investment scales and healthy balance sheets of major tech companies [29][30] - The capital expenditure of major cloud service providers is projected to increase significantly, reflecting strong demand for AI computing [35] Group 6 - Cultural and technological value output is becoming a major trend for Chinese enterprises going abroad, with significant growth in IP exports and innovative products in sectors like gaming and new dining [39][41] - The Chinese innovative pharmaceutical sector is increasingly integrated into the global supply chain, with more products commercialized in the US and Europe [41] Group 7 - Key sectors with strong overseas expansion opportunities in 2026 include new energy (batteries, grid equipment), machinery, TMT (technology, media, telecommunications), and innovative pharmaceuticals [46] - The gaming industry is also highlighted for its potential, with significant overseas revenue growth expected [49]

重要新闻提示 港交所主席唐家成指出，2026年以来，已有24只新股上市，集资额超过870亿港元，目前排队上市的企 业有488家。港交所今年将全力推进各项工作，包括公布提升上市制度和T+1的咨询文件。 特区政府财经事务及库务局副局长陈浩濂在香港黄金交易所农历年黄金启市日暨2026年新春开市仪式上 表示，为进一步多元发展香港的国际金融业务，特区政府正全力推动香港成为国际黄金交易中心。陈浩 濂说，将以三年超越2000吨为拓展在港黄金仓储的目标，打造香港成为区域黄金储备枢纽。在推动大宗 商品交易方面，目前已有15个伦敦金属交易所认可的仓库在香港营运。港交所也会深化与广州期货交易 所及内地其他大宗商品市场的联通发展。 春节假期商品消费需求旺盛，智能眼镜、智能血糖仪等智能产品备受青睐 国家发展改革委将重点从四方面推动现代化首都都市圈建设 2026春节档档期总票房（含预售）突破39亿元；2026年年度电影总票房（含预售）突破60亿元 1. 据央视新闻2月20日报道，商务大数据显示，春节假期前四天，全国重点零售和餐饮企业日均销售额 较2025年假期前四天增长8.6%。 商品消费需求旺盛。以旧换新政策效应持续显现，截至2月19 ...

本文源自：金融界AI电报 据香港交易所披露，摩根大通对无锡药明康德新药开发股份有限公司 - H股的多头持仓比例于2026年2 月12日从7.55%增至8.29%。 ...

该行料其2024至2027年的盈利年均复合增长率达24%，看好其独特的CRDMO/CTDMO模式及平台优 势，加上在中国竞争对手中拥有最多的早期项目数量，相较国内同业而言，为其中长期增长提供更强的 可见性。 智通财经APP获悉，摩根士丹利发布研报称，予药明康德(02359)"增持"评级，鉴于公司早前披露的2025 年初步业绩，因其毛利率上升，将其2026至2030年的盈利预测上调0%至3%，目标价因而由143港元升 至143.5港元。 ...

智通财经APP获悉，截止2月20日收盘，东北电气(00042)、京城机电股份(00187)、弘业期货(03678)分列 AH溢价率前三位，溢价率分别为800.00%、294.26%、292.86%；宁德时代(03750)、药明康德(02359)、 招商银行(03968)分列AH溢价率末三位，溢价率分别为-15.74%、-5.50%、-3.71%。其中京城机电股份 (00187)、剑桥科技(06166)、弘业期货(03678)的偏离值位居前三，分别为23.37%、23.34%、22.07%；另 外，晨鸣纸业(01812)、中海油田服务(02883)、钧达股份(02865)的偏离值位居后三，分别 为-59.49%、-29.71%、-25.40%。 | 凯盛新能(01108) | | | | | | --- | --- | --- | --- | --- | | 南华期货股份 | 10.200 | 18.34 | 115.39% | 16.88% | | (02691) | | | | | | 泰格医药(03347) | 48.800 | 64.4 | 58.07% | 13.30% | | 中州证券(01375) ...

Core Insights - The CRO (Contract Research Organization) industry in China is a strategic emerging industry that supports pharmaceutical innovation and is crucial for the transition from a pharmaceutical power to a pharmaceutical stronghold [1][9] - The development of policies for the CRO industry has evolved from a focus on the overall biopharmaceutical sector to specialized areas, emphasizing innovation, safety, and supply chain security [1][3] Policy Development History - The policy evolution from the "Tenth Five-Year Plan" to the "Fourteenth Five-Year Plan" has progressively recognized the importance of the CRO industry, with increasing support for specialized services [1] - The "Fifteenth Five-Year Plan" emphasizes differentiated, high-value innovation alongside supply chain security [1] National Policy Summary and Interpretation - Since 2006, multiple national policies have been introduced to support the CRO service system, focusing on regulatory standards, clinical trial optimization, and international development [3][7] - Key policies include the establishment of the MAH (Marketing Authorization Holder) system and the optimization of review and approval processes [3][7] Key National Policies (2025 Outlook) - Policies from 2006 to 2025 highlight the strategic importance of biopharmaceuticals and the CRO industry, with a focus on enhancing innovation capabilities and regulatory frameworks [4][5][6] - Recent policies aim to streamline clinical trial approvals and support the development of innovative drugs [6][10] Provincial and Municipal Policy Summary - Various provinces and cities have implemented supportive policies for the CRO industry, including investment subsidies, revenue rewards, and insurance subsidies, with some regions offering up to 50 million yuan in support [11][12] - Specific measures include allowing foreign investment in CROs and promoting AI integration in the industry [11][12][14] Provincial Development Goals - Regions like the Yangtze River Delta focus on high-end CRO service systems, while the Beijing-Tianjin-Hebei area emphasizes collaborative innovation and full-chain outsourcing [14] - Local governments aim to enhance the scale and service capabilities of the biopharmaceutical industry, with targeted initiatives for specific sectors such as seed industry CROs in Hainan [14]

港股马年首个交易日开盘，恒生指数低开0.18%，恒生科技指数跌0.69%。盘面上，油气板块强势，中 国海洋石油涨超2%；科网股集体走弱，阿里巴巴跌超3%。 关于港股后市 著名分析师张忆东在加盟国泰海通后，带领团队发布最新市场研判。首先，政策导向转为积极性和主动 性呵护中国股市。近期随着市场降温，上证4100点以下已经感受到托底的力量。其次，阶段性否极泰 来。港股整体卖空成交占比约19%，其中恒生科技指数卖空成交占比快速回升至21%。海外市场已出现 阶段性跌深反弹迹象，有利于港股短期反弹。 第三，保险为主的配置型战略投资者，开始趁市场调整而加大增持中国股市。第四，中国股市春季行情 的季节性规律，仍有望起作用。历史经验看，春节前市场若偏弱，节后随着资金回流与风险偏好修复， 市场往往更容易走强。中国基本面和资金面，才是决定中国股市行情的核心变量。后续各地两会、全国 两会、十五五规划实施、美国总统访华等一系列政治经济和产业层面的催化频出，内外资共振的增量资 金将推动今年春季行情。投资策略上可持股过节，享受春节红包，把握住近期市场调整倒车接客的时 机，布局2-3月的春季行情。 国联民生证券指出，港股科技前期表现显著滞涨 ...